Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel N Nafash

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Scientific Reports|April 18, 2026
Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurementsMarissa F Farinas, Yijun Chen, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformMarissa F Farinas, Yijun Chen, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Development of a Novel Blood-Based Assay for Brain-Derived Tau and Its Validation in Traumatic Brain InjuryWasiu G Balogun, Xuemei Zeng, Michel N Nafash, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassayMichel N Nafash, Sarah E Svirsky, Xuemei Zeng, et al.
Scientific Reports|February 21, 2026
Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassayMichel N Nafash, Sarah E Svirsky, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progressionXuemei Zeng, Marissa F Farinas, Michel N Nafash, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2026
BiomarkersXuemei Zeng, Rebecca A Deek, Michel N Nafash, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersLamia Choity, Xuemei Zeng, Rebecca A Deek, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Scientific Reports|April 18, 2026
Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurementsMarissa F Farinas, Yijun Chen, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformMarissa F Farinas, Yijun Chen, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Development of a Novel Blood-Based Assay for Brain-Derived Tau and Its Validation in Traumatic Brain InjuryWasiu G Balogun, Xuemei Zeng, Michel N Nafash, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassayMichel N Nafash, Sarah E Svirsky, Xuemei Zeng, et al.
Scientific Reports|February 21, 2026
Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassayMichel N Nafash, Sarah E Svirsky, Xuemei Zeng, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progressionXuemei Zeng, Marissa F Farinas, Michel N Nafash, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2026
BiomarkersXuemei Zeng, Rebecca A Deek, Michel N Nafash, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersLamia Choity, Xuemei Zeng, Rebecca A Deek, et al.
Pageof 1